Abstract：
:Previous studies have suggested that adherence to imatinib therapy can be an obstacle among patients with chronic myeloid leukemia (CML). We studied adherence to imatinib therapy among CML patients treated at the Sahlgrenska University Hospital. We identified all CML patients that were alive at the 1st of January 2010 (n = 70). Nineteen patients were excluded due to a history of allogenic hematopoietic stem cell transplantation, and nine were excluded due to treatment with other tyrosine kinase inhibitors. Thirty-eight out of 42 patients (90%) treated with imatinib accepted inclusion in the study. The patients were interviewed in a structured way, and adherence was evaluated in a standardized way using the nine-item Morisky Medication Adherence Scale that ranges from 1 to 13. A Morisky score ≤10 indicates nonadherence and ≥11 indicates adherence. In addition, predefined follow-up questions were asked to identify factors known to influence adherence to therapy. In contrast to previous studies, our patients showed good adherence to imatinib therapy with a mean Morisky score of 12.3 out of 13 (range, 9-13). The interviews revealed factors known to predict adherence to therapy, namely being well informed and having frequent contact with a single hematologist. Furthermore, the patients had easy access to the treating clinic and felt that they took part in decisions concerning their disease and treatment. We show that adherence to imatinib can be very good in CML patients, and we suggest that simple measures such as increased patient information and continuity of care will increase adherence in patients with CML.
journal_name
Ann Hematoljournal_title
Annals of hematologyauthors
Jönsson S,Olsson B,Söderberg J,Wadenvik Hdoi
10.1007/s00277-011-1359-0subject
Has Abstractpub_date
2012-05-01 00:00:00pages
679-685issue
5eissn
0939-5555issn
1432-0584pii
10.1007/s00277-011-1359-0journal_volume
91pub_type
杂志文章abstract：:Ixazomib, the first oral proteasome inhibitor (PI), has been approved for the treatment of relapsed refractory multiple myeloma (RRMM) in combination with lenalidomide and dexamethasone, based on the TOURMALINE-MM1 phase 3 trial, which demonstrated the efficacy and safety of this all-oral triplet, compared with lenali...
journal_title：Annals of hematology
pub_type： 杂志文章,多中心研究
doi：10.1007/s00277-020-03985-9
更新日期：2020-06-01 00:00:00
abstract：:Activation-induced cytidine deaminase (AID) is a mutator enzyme essential for somatic hypermutation (SHM) and class switch recombination (CSR) during effective adaptive immune responses. Its aberrant expression and activity have been detected in lymphomas, leukemias, and solid tumors. In chronic lymphocytic leukemia (...
journal_title：Annals of hematology
pub_type： 杂志文章
doi：10.1007/s00277-018-3520-5
更新日期：2019-02-01 00:00:00
abstract：:Patients with primary refractory or relapsed acute myeloid leukemia (AML) who undergo intensive salvage chemotherapy carry a high risk of treatment failure due to infectious complications and early relapses. The study presented here assessed the effect of granulocyte colony-stimulating factor (G-CSF) on the duration o...
journal_title：Annals of hematology
pub_type： 临床试验,杂志文章
doi：10.1007/s002770050425
更新日期：1998-09-01 00:00:00
abstract：:Marked polyclonal immunoglobulin (Ig)G4 hypergammaglobulinemia has exceptionally been reported. Here we report on two Algerian patients who presented a syndrome characterized by anemia, plasmacytic lymphadenopathy, renal manifestations, and a marked polyclonal IgG4 hypergammaglobulinemia leading to a hyperviscosity sy...
journal_title：Annals of hematology
pub_type： 杂志文章
doi：10.1007/s00277-006-0158-5
更新日期：2006-12-01 00:00:00
abstract：:Telomere shortening represents an established mechanism connecting aging and cancer development. We sequentially analyzed telomere length (TL) of 49 acute myeloid leukemia (AML) patients at diagnosis (n = 24), once they achieved complete cytological remission (CCR) and/or during refractory disease or relapse and after...
journal_title：Annals of hematology
pub_type： 杂志文章
doi：10.1007/s00277-017-3049-z
更新日期：2017-09-01 00:00:00
abstract：:HbE/Beta thalassemia (HbE/β-thalassemia) is one of the common genetic disorders in South East Asia. It is heterogeneous in its clinical presentation and molecular defects. There are genetic modifiers which have been reported to influence the disease severity of this disorder. The aim of this study was to determine the...
journal_title：Annals of hematology
pub_type： 杂志文章
doi：10.1007/s00277-020-03927-5
更新日期：2020-04-01 00:00:00
abstract：:Repeated courses of HD IVIg are reported to induce stable remission in a significant proportion of adults with chronic refractory ITP. We have treated 14 such patients obtaining a remission rate quite comparable to the 5-10% of spontaneous remission. ...
journal_title：Annals of hematology
pub_type： 临床试验,杂志文章
doi：10.1007/BF01834386
更新日期：1995-02-01 00:00:00
abstract：:The objective of this study was to evaluate retrospectively the clinical characteristics, treatments, and outcomes of patients with primary diffuse large B-cell lymphoma (DLBCL) of the female genital tract. The basic characteristics, treatments, and outcomes of six patients diagnosed with primary DLBCL of the female g...
journal_title：Annals of hematology
pub_type： 杂志文章
doi：10.1007/s00277-013-2003-y
更新日期：2014-06-01 00:00:00
abstract：:The present study attempted to build a single nucleotide polymorphism (SNP)-based risk model for predicting overall survival (OS) and event-free survival (EFS) in patients with core binding factor acute myeloid leukemia (CBF-AML). Adopting genome-wide SNP array using Affymetrix SNP array 6.0, we analyzed 868,157 SNPs ...
journal_title：Annals of hematology
pub_type： 杂志文章
doi：10.1007/s00277-018-3260-6
更新日期：2018-06-01 00:00:00
abstract：:In 1989, a prospective randomized multicenter study was initiated in order to determine the safety and efficacy of oral clodronate in myeloma patients. The primary objective of this long-term trial is to evaluate whether supportive clodronate is able to prevent or retard the progression of bone disease and reduce the ...
journal_title：Annals of hematology
pub_type： 临床试验,杂志文章,多中心研究,随机对照试验
doi：10.1007/BF01697625
更新日期：1993-03-01 00:00:00
abstract：:Treatment of acute lymphoblastic leukemia (ALL) requires the combination of multiple drugs to integrate a complete remission. The different prognostic factors (age, leukocytes, risk, cytogenetic alterations) allow identifying those patients with a high risk of relapse, but there are few described factors that impact t...
journal_title：Annals of hematology
pub_type： 杂志文章
doi：10.1007/s00277-020-04277-y
更新日期：2020-11-01 00:00:00
abstract：:An analysis was conducted in four members of the same family, two of whom had a history of severe bleeding associated with type 2B von Willebrand's disease (VWD) which, although found to be due to the same mutation, nevertheless exhibited different phenotype patterns in the two subjects involved. Von Willebrand's fact...
journal_title：Annals of hematology
pub_type： 杂志文章
doi：10.1007/s002770100303
更新日期：2001-06-01 00:00:00
abstract：:Gastrointestinal graft-versus-host disease (GVHD) is one of the main causes of therapy-related death after allogeneic hemopoietic stem cell transplantation. Early diagnosis and immediate treatment are probably essential for improving clinical outcome. High-resolution sonography allows the evaluation of single bowel wa...
journal_title：Annals of hematology
pub_type： 杂志文章
doi：10.1007/s00277-004-0893-4
更新日期：2005-01-01 00:00:00
abstract：:Haplo-identical transplants (Haplo-Tx) are an important alternative for patients with hematological malignancies who lack a HLA-identical donor. Seventy-one T-replete Haplo-Tx were performed in 70 high-risk patients at our center; 22/70 (31%) patients with refractory/relapsed leukemia received sequential salvage thera...
journal_title：Annals of hematology
pub_type： 临床试验,杂志文章
doi：10.1007/s00277-018-3433-3
更新日期：2018-11-01 00:00:00
abstract：:Despite recent advances made in its treatment, multiple myeloma (MM) remains an incurable B cell malignancy. Thus, the objective for treating these patients is to prolong overall survival (OS) and preserve patients' quality of life. We have analyzed data from 264 consecutive MM patients who had their initial visit bet...
journal_title：Annals of hematology
pub_type： 杂志文章
doi：10.1007/s00277-016-2888-3
更新日期：2017-03-01 00:00:00
abstract：:Reactivation of fetal hemoglobin synthesis in adulthood can be seen in hematological disorders affecting the erythropoietic system. The objective of the present study was to evaluate the incidence and prognostic significance of increased hemoglobin F in patients with myelodysplastic syndrome. Hemoglobin F concentratio...
journal_title：Annals of hematology
pub_type： 杂志文章
doi：10.1007/s002770050377
更新日期：1998-03-01 00:00:00
abstract：:Therapy-induced autoimmunity may mediate the destruction of cancer cells. Previous studies have demonstrated that presence of autoimmune thyroid disorder is associated with favorable outcome in patients with solid cancer. Patients with diffuse large B cell lymphoma (DLBCL) who achieved complete response on positron em...
journal_title：Annals of hematology
pub_type： 杂志文章
doi：10.1007/s00277-015-2311-5
更新日期：2015-06-01 00:00:00
abstract：:The aim of this review is to summarize the current knowledge on the clinical results of biotherapy of chronic myelogenous leukemia (CML) and potential mechanisms of the antitumor action of interferon alpha. IFN alpha treatment induces hematologic and cytogenetic remissions in patients with chronic phase CML. In additi...
journal_title：Annals of hematology
pub_type： 杂志文章,评审
doi：10.1007/BF01682030
更新日期：1995-03-01 00:00:00
abstract：:We analyzed the prognostic factors for a successful mobilization and peripheral blood stem cell collection in a series of 57 consecutive patients with multiple myeloma (MM); a new scoring system to predict an adequate mobilization in this subset of patients was also constructed. A total of 221 aphereses were performed...
journal_title：Annals of hematology
pub_type： 杂志文章
doi：10.1007/s002770100351
更新日期：2001-10-01 00:00:00
abstract：:Primary non-Hodgkin's lymphoma (NHL) of the genital tract is a rare entity. Etiology and pathogenesis of these NHLs are unknown, although there might be a possible association between chronic inflammation and lymphomas. The most common histological subtype is the diffuse large B-cell lymphoma. We report two cases of u...
journal_title：Annals of hematology
pub_type： 杂志文章
doi：10.1007/s00277-009-0741-7
更新日期：2009-12-01 00:00:00
abstract：:Despite high-dose chemotherapy and autografting, the outcome for patients with primary refractory Hodgkin's disease (HD) or multiple relapses remains unsatisfactory. Six pediatric patients (median age: 16 years, range: 11-19) received reduced intensity conditioning and allogeneic peripheral blood stem cell transplanta...
journal_title：Annals of hematology
pub_type： 杂志文章
doi：10.1007/s00277-003-0814-y
更新日期：2004-04-01 00:00:00
abstract：:Recent developments in the field of targeted therapy have led to the discovery of a new drug, plerixafor, that is a specific inhibitor of the CXCR4 receptor. Plerixafor acts in concert with granulocyte colony-stimulating factor (G-CSF) to increase the number of stem cells circulating in the peripheral blood (PB). Ther...
journal_title：Annals of hematology
pub_type： 杂志文章
doi：10.1007/s00277-010-1098-7
更新日期：2011-05-01 00:00:00
abstract：:We have studied some of the factors involved in the cytotoxic actions of the anticancer anthracycline antibiotics doxorubicin (DOX) and idarubicin (IDA) towards human B-cell lymphoma cells in vitro. IDA was found to accumulate within cells to a greater degree than the related drug DOX for both short (1 h) and long-ter...
journal_title：Annals of hematology
pub_type： 杂志文章
doi：10.1007/BF01757348
更新日期：1994-01-01 00:00:00
abstract：:High-dose chemotherapy with autologous peripheral blood stem cell transplantation (PBSCT) includes the risk of infectious complications due to neutropenia and therapy-induced immune deviation. In order to understand early immune recovery in this situation, we analyzed the distribution of cell subsets by flow cytometry...
journal_title：Annals of hematology
pub_type： 杂志文章
doi：10.1007/s00277-003-0716-z
更新日期：2003-10-01 00:00:00
abstract：:Follicular lymphoma (FL) is an indolent non-Hodgkin's lymphoma with heterogeneous outcomes. Progression or relapse of FL within 2 years (so-called POD24) after diagnosis is associated with a poor outcome for patients treated with R-CHOP (rituximab plus cyclophosphamide, doxorubicin, vincristine, prednisone) in clinica...
journal_title：Annals of hematology
pub_type： 杂志文章
doi：10.1007/s00277-020-04025-2
更新日期：2020-07-01 00:00:00
abstract：:Cerebral involvement is an unusual complication in multiple myeloma: herein four patients who presented myelomatous meningitis with multiple intraparenchymal lesions or a localized cerebral plasmacytoma are described. Two of these patients relapsed with meningeal involvement and a very limited disease outside the cent...
journal_title：Annals of hematology
pub_type： 杂志文章
doi：10.1007/s00277-001-0387-6
更新日期：2001-12-01 00:00:00
abstract：:Raised percentage hypochromic red cells (%HRC) were detected at diagnosis in 10 of 34 consecutive patients with low-risk myelodysplastic syndrome (MDS) [refractory anemia (RA) (4/26) and RA with ring sideroblasts (6/8)], all of whom had normal or increased serum ferritin and bone marrow iron stores. Elevated %HRC has ...
journal_title：Annals of hematology
pub_type： 杂志文章
doi：10.1007/s00277-006-0107-3
更新日期：2006-07-01 00:00:00
abstract：:There is little information about cardiovascular adverse event (CV-AE) incidence in chronic myeloid leukemia (CML) patients treated with bosutinib in the real-life practice. We identified 54 consecutive CML patients treated with bosutinib, stratified according to the Systematic Coronary Risk Evaluation (SCORE) assessm...
journal_title：Annals of hematology
pub_type： 杂志文章
doi：10.1007/s00277-019-03705-y
更新日期：2019-08-01 00:00:00
abstract：:A 4-day colorimetric tetrazolium dye (MTT) assay was used to assess the cytotoxicity of adriamycin (ADM), vincristine (VCR), and idarubicin (IDA) in blasts isolated from 37 patients with newly diagnosed and pretreated acute myeloid leukemia (AML). The effect of verapamil (VRP) as a chemosensitizer was studied in relat...
journal_title：Annals of hematology
pub_type： 杂志文章
doi：10.1007/BF01703946
更新日期：1992-11-01 00:00:00
abstract：:The efficacy of a single dose of MCNU 150 mg was evaluated in nine symptomatic patients with essential thrombocythemia (ET). As the platelet counts increased during the following 4 weeks, an extra dose of 100 mg of MCNU was administered to three patients. All patients had thrombotic or hemorrhagic complications. Seven...
journal_title：Annals of hematology
pub_type： 杂志文章
doi：10.1007/BF01738474
更新日期：1993-05-01 00:00:00
